NasdaqCM:CELCBiotechs
Celcuity (CELC) Is Up 176.2% After Positive Phase 3 Breast Cancer Results — Has the Bull Case Changed?
Celcuity Inc. recently announced positive topline results from the Phase 3 VIKTORIA-1 trial, where its investigational drug gedatolisib, combined with fulvestrant with or without palbociclib, significantly reduced the risk of disease progression or death in HR+/HER2- advanced breast cancer patients.
This breakthrough included a 76% improvement in disease progression risk reduction for the triplet therapy group and is expected to form the basis for a New Drug Application submission to the FDA...